§ 01 Overview
Overview
Synthetic 28-aa vasoactive intestinal peptide. FDA denied EUA twice for COVID-19; orphan designation for ARDS and pulmonary hypertension.
FDA denied EUA in 2021 and 2022 after ACTIV-3b futility.
§ 02 Mechanism
Mechanism of action
Aviptadil (synthetic VIP) is a VPAC1/VPAC2 agonist on alveolar type II cells that drives surfactant production and attenuates cytokine-mediated injury. It also has enteric and vascular effects.
- 01Surfactant production in alveolar type II cells
- 02Anti-cytokine effects
- 03Orphan designation for ARDS and PAH
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- Trial-dependent
- Route
- Other
- Frequency
- Trial-dependent (IV infusion)
§ 04 Evidence
Evidence & research
FDA denied EUA in 2021 and 2022 after ACTIV-3b futility.
FDA Status
Not FDA-approved. Orphan designation for ARDS and PAH.
§ 06 News
In the news
3 articles from the last 12 months · updates hourly
Vasoactive Intestinal Peptide (VIP)-Secreting Neuroblastic Tumors in Children Presenting With Chronic Secretory Diarrhea: A Report of Two Cases - Cureus
Vasoactive Intestinal Peptide (VIP)-Secreting Neuroblastic Tumors in Children Presenting With Chronic Secretory Diarrhea: A Report of Two Cases Cureus
Optogenetics Restores Motor Learning in Huntington’s - Neuroscience News
Optogenetics Restores Motor Learning in Huntington’s Neuroscience News
Marmoset superior colliculus: neuronal expression of somatostatin but not vasoactive intestinal peptide or neuropeptide Y - Frontiers
Marmoset superior colliculus: neuronal expression of somatostatin but not vasoactive intestinal peptide or neuropeptide Y Frontiers
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
Telehealth (Rx) · 1
Blokes / Joi Women's Wellness
Rx requiredMen's + women's optimization platform. TRT in 34 states. 4.6–4.8 Trustpilot.
Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →
§ 09 Safety
Safety & side effects
Side effects
- 01Hypotension
- 02Diarrhea
- 03Flushing
Contraindications
None specified.
§ 10 Questions
VIP / Aviptadil (Zyesami) FAQ
- What is VIP / Aviptadil (Zyesami)?
- Synthetic 28-aa vasoactive intestinal peptide. FDA denied EUA twice for COVID-19; orphan designation for ARDS and pulmonary hypertension. Aviptadil (synthetic VIP) is a VPAC1/VPAC2 agonist on alveolar type II cells that drives surfactant production and attenuates cytokine-mediated injury. It also has enteric and vascular effects.
- What is VIP / Aviptadil (Zyesami) used for?
- Reported uses include surfactant production in alveolar type ii cells, anti-cytokine effects, and orphan designation for ards and pah. Evidence strength is rated Clinical — see the evidence section for detail.
- How is VIP / Aviptadil (Zyesami) dosed?
- Commonly referenced dosing is Trial-dependent, typically trial-dependent (iv infusion), administered Other. This is educational reference only; consult a licensed clinician before use.
- What are the side effects of VIP / Aviptadil (Zyesami)?
- Commonly reported side effects include hypotension, diarrhea, and flushing. This list is not exhaustive.
- Is VIP / Aviptadil (Zyesami) legal?
- Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Not FDA-approved. Orphan designation for ARDS and PAH..
§ 11 References
Selected references
- 01
RLF-100 program
NCT04311697
- 02
ACTIV-3b TESICO
NCT04843761
- 03
Youssef review
PMID: 32837557